<DOC>
	<DOCNO>NCT00981084</DOCNO>
	<brief_summary>The investigation involve double-blind , placebo control , cross-over study examine efficacy armodafinil improve neurocognitive function reduce cognitive fatigue MS . Patients report MS-related cognitive difficulty perform least 1 standard deviation mean brief cognitive screen give thorough neuropsychological evaluation two time point . Half patient randomize receive single oral dose lactose placebo prior first test session . After washout period one week , receive 250mg armodafinil prior second test session ( P/A group ) . The half patient randomize receive active drug first . After washout period one week , receive placebo prior second test session ( A/P group ) . As plasma level armodafinil peak 2-4 hour administration , participant ask take single 250mg capsule 2 hour prior schedule testing session .</brief_summary>
	<brief_title>Impact Armodafinil Neurocognition Cognitive Fatigue Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>relapse remit secondary progressive MS patient age 18 60 report cognitive difficulty . perform 1 sd cutoff cognitive screening measure history alcohol/drug abuse nervous system disorder MS sensory impairment might interfere significantly cognitive test developmental history learn disability attentiondeficit/hyperactivity disorder medical condition MS could substantially affect cognition relapse and/or corticosteroid use within four week assessment ; current use modafinil , armodafinil psychostimulants .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>